Israel’s renowned Democracy Institute (IDI) has criticized the country’s agreement with corona vaccine manufacturer Pfizer. Institute member Tehilla Shwartz Altshuler said on Monday: “ The agreement contains one of the most extensive human studies in the 21st century, and Israel’s wealth of data will be available to the rest of the world for scientific research.”
Israel secured a large amount of the vaccine from the manufacturers BioNTech and Pfizer early on. The agreement between Israel and Pfizer provides, among other things, for the transmission of vaccination data to the vaccine manufacturer. The deal was published on Sunday, but many passages are censored.
Shwartz Altshuler said the deal could be seen as an achievement for Israel in its quest to be the first country to emerge from the pandemic. Nevertheless, the so-called Helsinki Committee in Israel, which is responsible for the approval of studies on humans, should have approved this first. Shwartz Altshuler said that one should have obtained the consent of the Israelis to use their health data.
One of the biggest problems with the agreement is that, while it stressed the need to protect Israeli privacy, it did not specify any concrete steps. It is known that the anonymity of big data can be removed.
The refore, the agreement in its current form may violate the protection of the health data of all Israelis.
A little over nine million people live in Israel. A massive vaccination campaign has been running parallel to the third wave for a month. So far, around 2.1 million people in Israel have received a first dose and almost 310,000 people have received a second dose.
The chairman of the board and majority owner of the publisher Börsenmedien AG, Mr. Bernd Förtsch, has taken direct and indirect positions on the following financial instruments mentioned in the publication or related derivatives that benefit from the publication of any resulting price development: BioNTech.
The author holds positions directly on the following financial instruments referred to in the publication or related derivatives that benefit from any price development resulting from the publication: BioNTech.
(With material from dpa-AFX)
[ source link ]
BioNTech vaccine country emerge pandemic criticism